Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 4/20 | 0.43 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 4/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 4/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
| ▸ | MET | P08581 | 1/20 | 0.32 |
| ▸ | RPS6KA3 | P51812 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3094563 | 0.84 | NOTUM (0.56) | NOTUMPDE3BPDE3AP2RX7IDO1 | |
| SCHEMBL3340311 | 0.80 | NOTUM (0.36) | NOTUMPDE3BPDE3AP2RX7MET | |
| SCHEMBL17151369 | 0.78 | SCN4A (0.46) | NOTUMP2RX7IDO1 | |
| SCHEMBL3342950 | 0.77 | BRD4 (0.43) | NOTUMPDE3BPDE3AP2RX7IDO1 | |
| Hydrochloric Acid SCHEMBL30015576 | 0.76 | SCN4A (0.45) | NOTUMP2RX7IDO1 | |
| SCHEMBL2326304 | 0.76 | NOTUM (0.40) | NOTUMPDE3BPDE3AP2RX7 | |
| SCHEMBL1456892 | 0.76 | HCAR2 (0.41) | NOTUMIDO1 | |
| SCHEMBL3340308 | 0.76 | BTK (0.38) | NOTUMP2RX7 | |
| SCHEMBL918364 | 0.73 | SCN4A (0.52) | NOTUMMETRPS6KA3 | |
| SCHEMBL3342946 | 0.72 | BTK (0.43) | NOTUMP2RX7IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9221806-B2 | 2-(heterocyclylbenzyl)pyridazinone derivatives | MERCK PATENT GMBH (DE) | 2015-12-29 | — | — | US | disclosed |
| US-20130131037-A1 | 2-(HETEROCYCLYLBENZYL)PYRIDAZINONE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRAENKTER HAFTUNG (DE) | 2013-05-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131037-A1 | 2-(HETEROCYCLYLBENZYL)PYRIDAZINONE DERIVATIVES | RET, MET, ERBB2 | NOTUM 4069/4885AR 1288/4885AKR1C3 1736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.